Source comparison
MOTS-c 20s Protocol: Comparison of Research Dosing Strategies
2x weekly (Mon/Thu) 10–20mg Insulin sensitivity maintenance Fasting insulin reduction 15–20%, improved glucose disposal post-meal Minimal injection frequency, easier compliance Best for metabolically healthy individuals seeking baseline preservation without in
This comparison does not assign a generated winner or score.
- 2x weekly (Mon/Thu)
- 10–20mg
- Insulin sensitivity maintenance
- Fasting insulin reduction 15–20%, improved glucose disposal post-meal
- Minimal injection frequency, easier compliance
- Best for metabolically healthy individuals seeking baseline preservation without intensive monitoring
- 3x weekly (Mon/Wed/Fri)
- 15–30mg
- AMPK activation, mitochondrial biogenesis
- Enhanced lactate clearance, VO2 max preservation, reduced oxidative stress markers
- Standard research protocol, well-documented safety profile
- Optimal balance between signaling frequency and total exposure for preventive use
- 5x weekly (weekdays)
- 25–50mg
- Maximal glucose uptake enhancement
- Significant HbA1c reduction in pre-diabetic populations (not applicable to healthy 20s), muscle glycogen storage improvement
- Higher injection burden, diminishing returns in non-dysfunctional populations
- Overkill for preventive application. Reserved for therapeutic contexts or metabolic correction
- Pulsed dosing (1 week on, 1 week off)
- Variable (10–30mg during 'on' weeks)
- Metabolic flexibility testing
- Sustained insulin sensitivity during off-weeks, less peptide exposure overall
- Requires disciplined cycling, harder to track cumulative effects
- Interesting experimental approach but lacks long-term outcome data in healthy populations
- The bottom line: for MOTS-c 20s age specific protocol application, 3x weekly dosing at 5–10mg per injection (15–30mg total weekly) aligns best with research demonstrating sustained AMPK activation and insulin sensitivity improvements without the injection fatigue or diminishing returns seen at higher frequencies.